With a market cap of $7.5 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, ...

According to a Feb. 17, 2026, SEC filing, Hollow Brook Wealth Management LLC sold out its entire position in Bio-Techne (NASDAQ:TECH) during the fourth quarter of 2025. The fund divested 174,677 ...

Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...

Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities.

Shares of Bio-Techne Corp. TECH advanced 1.43% to $47.37 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.17% to 7,445.72 ...

Bio-Techne Corp. TECH recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Bio-Techne (NASDAQ:TECH) is preparing to release its quarterly earnings on Wednesday, 2026-02-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Bio-Techne is a leading provider of specialized reagents, analytical instruments, and diagnostic solutions for the life sciences and clinical diagnostics sectors. The company leverages a diverse ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...